Gunesacar R, Erken E, Bozkurt B, Ozer H T, Dinkci S, Erken E G, Ozbalkan Z
Department of Rheumatology-Immunology, Cukurova University Faculty of Medicine, Balcali, Tr-01330, Adana, Turkey.
Int J Immunogenet. 2007 Feb;34(1):45-9. doi: 10.1111/j.1744-313X.2007.00655.x.
In this study we aimed to investigate IVS3 +17T/C single nucleotide polymorphism (SNP) of CD28 gene, +49A/G and -318C/T SNPs of CTLA-4 gene in patients with Behçet's disease (BD) and their potential association to the main clinical features of the disease. These polymorphisms were investigated in a Turkish population of 123 patients with BD and 179 healthy controls, by using PCR-RFLP technique. HLA-B51 genotype was also studied in both groups by using PCR-SSP. The frequency of IVS3 +17TC genotype of the CD28 gene was significantly increased in BD patients compared to controls (43.6% vs. 31.2%, OR = 1.663, 95% CI = 1.033-2.679, P = 0.039). CTLA-4 +49GG genotype frequency was found to be significantly lower in patients with BD than those of healthy controls (4% vs. 10.6%, OR = 0.357, 95% CI = 0.130-0.983, P = 0.05). Genotype and allele frequencies of the CTLA-4-318C/T polymorphism between the BD and healthy control groups were not significantly different (12.2% vs. 10.6%, OR = 1.170, 95% CI = 0.570-2.402, P = 0.713). There were no associations between the studied polymorphisms and the main clinical features of BD. The frequencies of HLA-B51 were 60.3% and 30.7% in BD and control groups, respectively (OR = 3.429, 95% CI = 2.115-5.559, P = 0.0001). Association between HLA-B*51 and each studied polymorphism did not reach to significant levels (OR = 0.479, 95% CI = 0.228-1.004, P = 0.064 for CD28 IVS3 +17TT genotype; OR = 2.180, 95% CI = 1.025-4.639, P = 0.061 for TC genotype; OR = 1.570, 95% CI = 0.870-2.836, P = 0.146 for C allele). These results may suggest that CD28 IVS3 +17TC genotype may be a risk factor for the development of BD, on the contrary CTLA-4 +49GG genotype may be protective in the studied Turkish population.
在本研究中,我们旨在调查白塞病(BD)患者中CD28基因IVS3 +17T/C单核苷酸多态性(SNP)、CTLA-4基因+49A/G和-318C/T SNP及其与该疾病主要临床特征的潜在关联。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术,在123例BD患者和179例健康对照的土耳其人群中对这些多态性进行了研究。同时采用聚合酶链反应-序列特异性引物(PCR-SSP)技术对两组的HLA-B51基因型进行了研究。与对照组相比,BD患者中CD28基因IVS3 +17TC基因型的频率显著升高(43.6%对31.2%,OR = 1.663,95%可信区间[CI] = 1.033 - 2.679,P = 0.039)。发现BD患者中CTLA-4 +49GG基因型频率显著低于健康对照组(4%对10.6%,OR = 0.357,95% CI = 0.130 - 0.983,P = 0.05)。BD组与健康对照组之间CTLA-4 -318C/T多态性的基因型和等位基因频率无显著差异(12.2%对10.6%,OR = 1.170,95% CI = 0.570 - 2.402,P = 0.713)。所研究的多态性与BD的主要临床特征之间无关联。BD组和对照组中HLA-B51的频率分别为60.3%和30.7%(OR = 3.429,95% CI = 2.115 - 5.559,P = 0.0001)。HLA-B*51与每个研究的多态性之间的关联未达到显著水平(CD28 IVS3 +17TT基因型的OR = 0.479,95% CI = 0.228 - 1.004,P = 0.064;TC基因型的OR = 2.180,95% CI = 1.025 - 4.639,P = 0.061;C等位基因的OR = 1.570,95% CI = 0.870 - 2.836,P = 0.146)。这些结果可能表明,在研究的土耳其人群中,CD28基因IVS3 +17TC基因型可能是BD发病的一个危险因素,相反,CTLA-4 +49GG基因型可能具有保护作用。